Braeburn Pharmaceuticals

May 14, 2018

Braeburn Announces Publication of Positive Phase 3 Results For Long-Acting Buprenorphine For Treatment Of Opioid Use Disorder in JAMA Internal Medicine

Apr 12, 2018

Braeburn Launches Brave Action

Jul 20, 2017

Braeburn and Camurus Announce Submission of NDA for Long-Acting Buprenorphine (CAM2038) for Opioid Use Disorder

Jul 12, 2017

Camurus and Braeburn Pharmaceuticals Announce Topline Phase 2 Results for Long-acting Buprenorphine in Opioid Dependent Patients with Chronic Pain

Jun 22, 2017

Phase 2 Trial Demonstrates Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms in Adults with Opioid Use Disorder

Jun 15, 2017

Braeburn Pharmaceuticals and Camurus Announce Presentations of Pivotal Clinical Study Data of Long-acting Buprenorphine

Jun 05, 2017

Braeburn Pharmaceuticals Names Michael M. Derkacz as President and CEO